Bromocriptine use and the risk of valvular heart disease
Identifieur interne : 000B50 ( Main/Exploration ); précédent : 000B49; suivant : 000B51Bromocriptine use and the risk of valvular heart disease
Auteurs : Louis C. S. Tan [Singapour] ; Kenneth K. C. Ng [Singapour] ; Wing-Lok Au [Singapour] ; Raymond K. K. Lee [Singapour] ; Yiong-Huak Chan [Singapour] ; Nigel C. K. Tan [Singapour]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-02-15.
English descriptors
- KwdEn :
Abstract
It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot‐derived dopamine agonist (DA) with partial 5‐HT2B activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy‐two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11–9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22–10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate‐severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose‐dependent manner. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22228
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bromocriptine use and the risk of valvular heart disease</title><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name></author><author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name></author><author><name sortKey="Au, Wing Ok" sort="Au, Wing Ok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name></author><author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name></author><author><name sortKey="Chan, Yiong Uak" sort="Chan, Yiong Uak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name></author><author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D270A4B1CEBEB5E911D82E135771EC449CCB7D5</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22228</idno><idno type="url">https://api.istex.fr/document/2D270A4B1CEBEB5E911D82E135771EC449CCB7D5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001831</idno><idno type="wicri:Area/Main/Curation">001586</idno><idno type="wicri:Area/Main/Exploration">000B50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Bromocriptine use and the risk of valvular heart disease</title><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><affiliation><wicri:noCountry code="subField">USA National Parkinson Foundation Centre of Excellence</wicri:noCountry></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Neurology, National Neuroscience Institute</wicri:regionArea><wicri:noRegion>National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Cardiology, Tan Tock Seng Hospital</wicri:regionArea><wicri:noRegion>Tan Tock Seng Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Au, Wing Ok" sort="Au, Wing Ok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name><affiliation><wicri:noCountry code="subField">USA National Parkinson Foundation Centre of Excellence</wicri:noCountry></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Neurology, National Neuroscience Institute</wicri:regionArea><wicri:noRegion>National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Cardiology, Tan Tock Seng Hospital</wicri:regionArea><wicri:noRegion>Tan Tock Seng Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Yiong Uak" sort="Chan, Yiong Uak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><affiliation wicri:level="4"><country xml:lang="fr">Singapour</country><wicri:regionArea>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Neurology, National Neuroscience Institute</wicri:regionArea><wicri:noRegion>National Neuroscience Institute</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-02-15">2009-02-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="344">344</biblScope><biblScope unit="page" to="349">349</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2D270A4B1CEBEB5E911D82E135771EC449CCB7D5</idno><idno type="DOI">10.1002/mds.22228</idno><idno type="ArticleID">MDS22228</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5‐HT2 serotonin receptors</term><term>bromocriptine</term><term>dopamine agonists</term><term>ergotamines</term><term>pergolide</term><term>valvular heart disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot‐derived dopamine agonist (DA) with partial 5‐HT2B activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy‐two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11–9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22–10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate‐severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose‐dependent manner. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Singapour</li></country><orgName><li>Université nationale de Singapour</li></orgName></list><tree><country name="Singapour"><noRegion><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name></noRegion><name sortKey="Au, Wing Ok" sort="Au, Wing Ok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name><name sortKey="Chan, Yiong Uak" sort="Chan, Yiong Uak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2D270A4B1CEBEB5E911D82E135771EC449CCB7D5
|texte= Bromocriptine use and the risk of valvular heart disease
}}
| This area was generated with Dilib version V0.6.23. |  |